Continuing Education Activity

The rising prevalence of overweight and obesity presents a global public health challenge. Weight reduction is the primary intervention, which leads to metabolic adaptations that are mostly beneficial to overall health. A direct link exists between weight loss and improvement in metabolic diseases such as hypertension, insulin resistance, pre-diabetes, type 2 diabetes, dyslipidemias, and sleep apnea, as well as comorbidities such as metabolic dysfunction–associated steatotic liver disease (MASLD), polycystic ovarian syndrome, and infertility. However, weight reduction also triggers adverse compensatory metabolic effects, including declines in satiety hormones such as leptin and elevations in hunger-stimulating pathways, which drive appetite surges and slow energy expenditure. 

This activity will discuss the metabolic mediators and effectors involved in weight management after weight loss. It also highlights the role of the interprofessional team, including physicians, nurses, laboratory staff, nutritionists, physiotherapists, exercise physiologists, and trainers, in helping individuals maintain a healthy weight after weight loss.

Objectives:

• Identify metabolic adaptations that occur during weight loss and their impact on long-term weight maintenance and the risk of weight regain.
• Assess the clinical impact of fluctuations in peripheral gut-brain hormones on post-weight-loss appetite surges and compensatory overeating.
• Implement evidence-based management strategies, such as dietary modifications, tailored pharmacotherapy, structured physical activity, and bariatric surgery, to counteract compensatory physiological responses and support the maintenance of a healthy body weight following weight reduction.
• Collaborate with the interprofessional healthcare team to coordinate treatment plans, including lifestyle modifications, exercise training, pharmacologic therapy, and surgical interventions, to address the metabolic consequences of weight reduction and optimize long-term weight management. 

Access free multiple choice questions on this topic.

Introduction

Metabolism refers to the physiologic processes that regulate how the body stores, uses, and expends energy and plays a central role in body weight regulation. Energy intake and physical activity, along with genetic, hormonal, behavioral, and environmental factors, influence body weight. When individuals with overweight or obesity lose weight, physiologic adaptations may reduce energy expenditure and increase appetite, leading to weight regain. After weight loss, healthy eating habits, regular exercise, and adequate sleep can promote metabolic health and support weight maintenance.

Globally, obesity and overweight have reached epidemic proportions and are a major public health concern. As of 2026, more than 2.5 billion adults worldwide have overweight or obesity, with obesity rates tripling since 1975 in most resource-rich regions.[1] Obesity is defined as a BMI ≥ 30, and overweight as a BMI between 25 and 29.9. BMI assesses an individual's body weight relative to their height but does not directly measure body fat. However, it is a useful and inexpensive screening tool for clinical and research purposes. For individuals of Asian descent, the World Health Organization uses lower BMI cutoffs of 23 and 25, respectively, to define overweight and obesity because data show that they generally have a higher percentage of body fat and an elevated risk of cardiovascular disease and type 2 diabetes at lower BMIs than other populations.[2][3]

Obesity is associated with several comorbidities, including type 2 diabetes, cardiovascular disorders, liver and kidney disease, gastrointestinal conditions, sleep apnea, osteoarthritis, and certain malignancies, including endometrial, esophageal, gastric, kidney, colorectal, liver, gallbladder, pancreatic, prostate, postmenopausal breast, ovarian, and thyroid cancers.[4][5][6][7][8][9] Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is now recognized as one of the most common obesity-related conditions, affecting approximately 30% of adults worldwide and up to 70% of individuals with obesity.[10] Research indicates that obesity may disrupt the body's metabolic and immunological axis, increasing the risk of severe illnesses, including COVID-19 and other infections.[11][12] Notably, long-term weight-loss maintenance is linked to improvements in many health risk factors.[13] 

Maintaining a healthy body weight after weight loss requires balancing energy intake and expenditure to support optimal metabolism. Physiologically, this involves regulating enzyme activity, ATP synthesis and utilization, hormonal function, and neurological and muscular activity. Weight loss produces both beneficial metabolic changes and compensatory responses that favor weight regain. Understanding these adaptations is important for designing effective weight-loss programs, managing obesity-related chronic diseases, and supporting the long-term maintenance of a healthy weight. 

This activity examines the metabolic mechanisms triggered by weight loss, including changes in energy expenditure, appetite-regulating hormones, substrate metabolism, and neurobehavioral reward pathways, as well as their timing and magnitude and how they contribute to weight regain. It reviews clinical implications and evidence-based strategies, including behavioral, dietary, exercise, pharmacologic, and surgical interventions, to mitigate compensatory adaptations, promote metabolic health, and improve long-term maintenance of a healthy weight.   

Function

Metabolism encompasses the processes that convert nutrients into energy and synthesize the compounds cells need to maintain bodily functions. The energy from these biochemical pathways is primarily stored as adenosine triphosphate (ATP) to meet cellular demands. A continuous supply of ATP, both during activity and at rest, is fundamental to the metabolic processes that sustain life. At rest, the body requires energy to support activities such as breathing, maintaining blood circulation, brain function, cellular growth and repair, and basic hormonal and neurological processes.[14] 

Total energy expenditure (TEE) is divided into 3 components: the basal metabolic rate (BMR) or resting metabolic rate (RMR), the thermic effect of food, and physical activity (both exercise and non-exercise movement). BMR and RMR are often used interchangeably, but BMR reflects the absolute minimum energy required for essential physiologic functions, whereas RMR represents the energy expended at rest and may include minor movement and emotional arousal. RMR is easier to measure and more commonly used in clinical practice; it can be up to 10% higher than BMR, which usually accounts for 60-75% of TEE.[15] The thermic effect of food is the energy expenditure associated with digesting, metabolizing, and storing dietary nutrients, typically less than 10% of TEE. Physical activity energy expenditure ranges from 15% to 30% of TEE and represents the energy cost of voluntary movement.[16]

In the initial phase of calorie restriction, the reduction in energy intake exceeds the reduction in energy expenditure (EE), creating an energy deficit and leading to weight loss. Because EE correlates with body mass, weight loss, in turn, reduces EE. Over time, a calorie-restriction regimen establishes an energy intake-EE balance. This decline in EE, proportionate to smaller body mass, is termed metabolic adaptation. During a calorie-restriction regimen, metabolic adaptation at rest and during activity correlates with weight loss.[17] This balance is maintained not only by metabolic changes but also by compensatory behavioral mechanisms that conserve energy. Evidence suggests that circulating hormones, including leptin, thyroid hormones, and insulin, mediate responses to calorie restriction by modulating heart rate, blood pressure, and sympathetic nervous system activity.[18] Metabolic adaptation is specific to calorie restriction; weight loss from exercise alone does not induce it.[19]

Weight reduction yields both metabolic benefits and compensatory physiological adaptations that resist further weight loss and promote weight regain. Despite improved metabolic profiles, the net effect is often a physiological "defense" of the previous, higher body weight. Reduced TEE and hormonal changes that increase hunger favor weight regain.

Beneficial Metabolic Consequences

• Insulin Sensitivity and Glycemic Control 

As little as a 5% reduction in body weight improves insulin sensitivity in the liver, skeletal muscle, and adipose tissue and enhances pancreatic β-cell function.[20][21] Further weight loss yields dose-dependent improvements. A meta-analysis found that ≥5% total weight loss was associated with a higher likelihood of diabetes remission than <5% loss and with clinically significant reductions in HbA1c and fasting glucose. The Look AHEAD trial demonstrated that an 8.6% weight loss was associated with a 0.64% reduction in HbA1c, and the Diabetes Prevention Program showed a 58% relative reduction in diabetes incidence with ~5.6 kg of weight loss.[21] 

• Lipid Profile

Weight reduction typically lowers triglycerides and increases HDL cholesterol. Total and non-HDL cholesterol decrease significantly, and LDL subfractions shift toward a less atherogenic profile.[22][23]

• Blood Pressure

Systolic and diastolic blood pressure typically decrease by about 5/4 mmHg with a 5-7% reduction in weight.[24]  

• Inflammation and Endothelial Function

A ≥5% weight loss significantly reduces levels of peripheral pro-inflammatory cytokines, including IL-6, TNF-α, IL-8, and hs-CRP, thereby lowering an individual's overall inflammatory score.[23]

• Hepatic and Ectopic Fat

Progressive weight loss reduces intrahepatic triglyceride content and ectopic fat in the pancreas and muscle, thereby lowering lipotoxicity and improving organ-specific insulin sensitivity.[20]

• Oxidative Stress and Mitochondrial Function

Calorie restriction-induced deceleration of metabolic rate limits the mitochondrial generation of reactive oxygen species (ROS), which otherwise disrupt molecular and cellular structure and function. Diminished ROS production, in turn, alleviates homeostatic and functional impairments.[25] Weight loss also increases glutathione levels and antioxidant enzyme expression, and improves basal and maximal mitochondrial respiration and ATP production.[26] Consequently, calorie-restriction-induced weight loss reduces oxidative damage and improves metabolic health.[17][26]

Counterregulatory Adaptive Responses

• Reduced Energy Expenditure (Adaptive Thermogenesis)

Weight loss triggers a disproportionate decline in TEE relative to changes in body composition. This lower TEE is an energy-conserving response that serves as a biological defense against starvation and is called adaptive thermogenesis. A 10% reduction in body weight results in approximately a 15% decrease in TEE (about 375 kcal/day based on a 2,500 kcal intake), affecting both resting and non-resting components.[Clinical Management of Obesity- Third Edition.The Obesity Society (2025). Caroline M. Apovian MD, Louis Aronne MD, Sarah R. Barenbaum MD]  Adaptive thermogenesis appears as early as a 5% weight loss, resulting in a lower RMR, and at a 10% weight loss, resulting in lower resting and exercise-induced energy expenditures.[27] This metabolic adaptation is driven primarily by total weight loss, not by the rate or timing of that loss. It may persist indefinitely as long as individuals maintain their reduced weight.[28] Contributing factors include disproportionate loss of high-metabolic-rate organ mass (liver, kidney, heart) and reduced thyroid hormone activity.[Clinical Management of Obesity- Third Edition.The Obesity Society (2025). Caroline M. Apovian MD, Louis Aronne MD, Sarah R. Barenbaum MD]

• Hormonal Adaptations Favoring Weight Regain
  • Leptin: Leptin is a key satiety hormone that signals the brain to suppress appetite when the body has sufficient energy stores. After a weight loss of approximately 5% of body weight, the reduction in fat mass leads to decreased leptin production by adipocytes. The subsequent drop in plasma leptin concentration creates a leptin-deficiency signal in the brain, which then induces a high-energy intake response characterized by increased hunger. At 10% body weight loss, brain leptin concentration declines significantly, further reducing satiety. An experimental observation reported that leptin injections in individuals during the weight-maintenance period reversed deficiency-related symptoms in brain areas dedicated to regulating energy intake, confirming an association between leptin and weight loss.[29][30][31] The correlation between plasma leptin, baseline BMI, and initial fat mass with the risk of weight regain suggests an active role for adipocytes. After fat loss, adipocytes experience cellular stress. Cells become smaller, affecting their structure-function axis.[32] Achieving a new homeostatic energy balance alleviates this stress by normalizing adipokine secretion and restoring efficient adipose and triglyceride storage. If individuals continue to consume excessive calories, adipocyte energy demands rise, further increasing the risk of weight regain.[33] 
  • Ghrelin: Ghrelin is the body's primary circulating orexigenic "hunger" hormone, stimulating appetite by activating hypothalamic AgRP/NPY neurons. Its levels generally fluctuate inversely with body weight, rising sharply during weight loss as a compensatory response. Elevated plasma ghrelin levels can persist for 1-2 years, promoting weight regain.[34][31][29] The exception is weight loss after bariatric surgery, during which patients may experience a drop in ghrelin levels.[35] 
  • Satiety hormones: PYY, gastric inhibitory peptide, GLP-1, CCK, and amylin decrease after weight reduction, further increasing appetite and food intake.[29][34] 
  • Thyroid Hormones: Weight loss induces a significant decrease in active triiodothyronine (T3), whereas thyroxine (T4) generally remains stable and thyroid-stimulating hormone (TSH) decreases modestly.[36]. This shift is primarily driven by reduced peripheral conversion of T4 to T3 and by decreased leptin levels.[37]  These changes represent an adaptive, energy-conservation response that lowers RMR, thereby promoting weight regain.[38] Studies demonstrate that diet-induced weight loss of about 6% of body weight reduces T3 levels without significantly altering baseline TSH or T4 levels.[36] Bariatric surgery has been found to trigger more pronounced changes, with decreases in both T3 and TSH between 6 and 12 months, which typically return to baseline after 1 year. Early evidence suggests that GLP-1 agonists are associated with lower TSH, decreased T4, and elevated T3, possibly due to enhanced peripheral conversion of T4 to T3. However, further research is needed to determine whether this is an effect of weight loss or a direct effect of GLP-1 agonists on the thyroid.[39]

Issues of Concern

Managing the metabolic consequences of weight reduction requires addressing several concerns, including changes in body composition, weight-loss plateaus or weight regain, and psychological factors that can compromise long-term treatment outcomes.

Sarcopenia and Lean Mass Depletion

Weight loss consistently results in a concomitant loss of lean body mass (LBM), more often referred to as fat-free mass (FFM).[40] Approximately 20% to 30% of total weight loss is FFM, with roughly half of that (about 10-15% in women, 20-25% in men) being skeletal muscle mass.[41] This muscle loss can accelerate age-related sarcopenia, impair physical function, and promote weight regain. Older adults over age 65 are the highest-risk group. Reduced FFM can contribute to frailty, falls, and fractures. 

Across lifestyle, pharmacologic, and bariatric surgery interventions, the proportion of total weight loss as FFM is similar when matched for the degree of weight loss. A 2026 meta-analysis of 20 RCTs (N = 15,782) reported a pooled estimate of 26.5% (95% CI: 24.2–28.8) of total weight loss as FFM across all modalities.[42]

Moderate-to-vigorous daily physical activity helps patients maintain weight loss and preserve FFM. Exercise stimulates muscle hypertrophy and drives structural reorganization of adipose tissue.[43] At the molecular level, exercise modulates key biochemical pathways, including activation of AMP-activated protein kinase (AMPK), increased plasma substrate uptake, lipid degradation, and mitochondrial function.[44] Adding exercise to caloric restriction can prevent nearly half of the expected loss of FFM.[45] A combination of resistance and aerobic exercise is the most effective intervention for preventing or reversing diet-induced sarcopenia, with resistance training alone a close second choice.[46] 

Adequate dietary protein intake will also help preserve lean mass, but without concomitant resistance training, it does not prevent declines in muscle strength or physical function.[47] Current clinical guidelines for patients who are losing weight recommend a protein intake of 1.2 to 1.6 g/kg/day, or about 80 to 120 g per day.[41]

Reduced Bone Mineral Density

Weight-loss-associated bone loss may occur and is most concerning in patients already at elevated fracture risk, particularly postmenopausal women, older adults, and those with pre-existing osteopenia.[48][49][50] The risk is typically low after lifestyle-induced weight loss but increases with the use of GLP-1 receptor agonists or bariatric surgery. Reduced bone mineral density results from a combination of factors, including reduced mechanical loading on weight-bearing bones, hormonal shifts (lower estrogen and leptin levels), nutritional deficiencies (calcium, protein, and vitamin D), increased bone turnover, and reduced muscle mass. Protective measures include adequate dietary protein, calcium 1000-1200 mg/day, vitamin D supplementation, and resistance training.[49][51] 

The Weight Loss Plateau and Patient Discouragement

The weight-loss plateau, typically occurring around 6–8 months, results from a combination of factors, including metabolic adaptation and hormonal shifts that promote appetite and increased caloric intake. Patients and clinicians may mistake these physiological defense mechanisms for a failure of willpower or non-adherence, leading to discouragement and high dropout rates.

While metabolic and hormonal changes reduce energy expenditure and increase appetite, mathematical modeling indicates that a progressive, often unconscious relaxation of dietary adherence is likely the primary driver of the weight-loss plateau. A deceleration in the rate of weight loss undermines motivation and further erodes adherence to recommended lifestyle interventions.[52] During this period, individuals may experience depressive symptoms, emotional eating, and psychological distress.[53] Helpful strategies include educating patients that the plateau is a predictable metabolic response to weight loss, not a personal failure. Other interventions include close professional follow-up, psychological support, high levels of physical activity, and anti-obesity medication.[54] 

Clinical Significance

The clinical significance of beneficial metabolic changes accompanying weight loss, including remission of type 2 diabetes, improved cardiometabolic profiles, and reduced cancer risk, is offset by counterregulatory adaptations that make sustained weight loss challenging and necessitate long-term treatment strategies.

The relationship among weight loss rate, total weight reduction, and subsequent metabolic effects is complex, and studies have reported conflicting results. While gradual weight loss has traditionally been championed as a more sustainable clinical approach, accumulating evidence suggests that greater initial weight loss increases the likelihood of successful long-term weight maintenance.[55] One possible contributing factor is that early success increases patient motivation and adherence to lifestyle measures that favor weight loss. Recent meta-analyses indicate that the rate of weight loss matters less than the total weight lost and the strategies used to achieve it. Specifically, weight reduction achieved with GLP-1 receptor agonist medications or bariatric surgery produces different metabolic adaptation profiles than those of diet-induced weight loss. Larger-magnitude weight reductions inherently trigger steeper counterregulatory metabolic adaptations, including profound drops in energy expenditure and fluctuations in appetite-regulating hormones, thereby priming the body for weight regain. Thus, greater early weight loss predicts more successful long-term maintenance despite these metabolic adaptations, not because of them.

The contemporary concept of "weight loss responsiveness" emphasizes that individuals vary widely in their baseline metabolic, endocrine, and behavioral responses to identical weight-loss interventions. Weight loss achieved through bariatric surgery or GLP-1 agonist therapies elicits metabolic adaptation profiles distinct from those induced by standard dietary therapy alone. Ultimately, optimizing long-term patient outcomes depends not only on initial weight loss but also on the timely implementation of sustained behavioral, pharmacologic, and lifestyle interventions tailored to individual biological responses.[56][57]

Disease Remission and Risk Reduction

Metabolic improvements are directly proportional to the amount of weight a patient loses. A meta-analysis of 43 studies found that ≥5% weight loss (vs. <5%) was associated with a 7.88-fold higher likelihood of type 2 diabetes remission, a 5.61-fold higher likelihood of metabolic syndrome remission, and a 2.23-fold higher likelihood of hypertension remission, with even greater benefits at ≥15% weight loss. The Look AHEAD trial confirmed this association: each incremental increase in weight loss (from ≥2% to ≥15%) was associated with progressively greater improvements in HbA1c, blood pressure, triglycerides, and HDL cholesterol.[28][24] [Clinical Management of Obesity- Third Edition.The Obesity Society (2025). Caroline M. Apovian MD, Louis Aronne MD, Sarah R. Barenbaum MD] The ADA Standards of Care (2026) emphasize that a minimum of 5% weight loss is needed for clinically meaningful metabolic improvements, with 15% or more recommended for maximum benefits when feasible.[58] 

Weight loss greater than 5% in patients with overweight or obesity improves insulin resistance, blood glucose levels, lipid profiles, blood pressure, MASLD, and osteoarthritis. It may also benefit sleep apnea, urinary incontinence, and depression.[59] Weight loss greater than 10% can lead to type 2 diabetes remission and lower the risk of atrial fibrillation, heart failure, and chronic kidney disease. Additional weight loss of greater than 15% further reduces renal disease progression, improves metabolic dysfunction–associated steatohepatitis, and reduces the risk of obesity-related cancers, cancer mortality, and all-cause mortality.[60][4]

Counterregulatory Adaptations

Persistent reductions in energy expenditure and unfavorable hormonal shifts (elevated ghrelin, reduced leptin, PYY, and GLP-1) are clinically significant because they favor weight regain. These changes persist for at least 1 year and likely last indefinitely. [Clinical Management of Obesity- Third Edition. The Obesity Society (2025). Caroline M. Apovian MD, Louis Aronne MD, Sarah R. Barenbaum MD] Changes in hunger hormones are associated with increased appetite, further compounding the challenge of maintaining a healthy BMI.[61]

Implications for Treatment Strategies

These findings support the recognition of obesity as a chronic disease requiring long-term management. The American Heart Association notes that modest short-term weight loss (5–10 kg) may not fully offset the harmful effects of long-term obesity on the vasculature, whereas the greater weight loss achieved with bariatric surgery (10–40 kg) has been associated with fewer cardiovascular events.[7] The persistence of metabolic adaptations provides the physiologic rationale for long-term pharmacotherapy (e.g., GLP-1 receptor agonists, GIP/GLP-1 dual agonists) or bariatric surgery rather than lifestyle interventions alone, because discontinuing treatment often leads to weight regain and the reversal of metabolic benefits.[62]

The absolute reduction in RMR or REE following weight loss is primarily determined by the total amount of weight and lean mass lost, rather than the specific modality used to achieve that loss.[63] Across lifestyle modifications, GLP-1 receptor agonists, and bariatric surgery, lean mass loss relative to overall weight loss remains remarkably consistent.[64] While bariatric surgery causes the largest absolute declines in REE due to greater reductions in organ and tissue mass, it also paradoxically increases weight-adjusted REE (kcal/kg/day) after surgery, likely due to altered diet-induced thermogenesis and gut hormone activity that promotes satiety.[65][66][67] 

The key clinical distinction among weight-loss interventions lies not in metabolic slowing but in the subsequent appetite response. GLP-1 agonists and dual GLP-1/GIP agonists, such as semaglutide and tirzepatide, may attenuate metabolic adaptation by preserving or improving metabolic efficiency per unit of lean tissue and by shifting substrate utilization toward greater fat oxidation.[68] Dual GLP-1/GIP agonists harness the complementary actions of both incretin hormones to modulate central and peripheral pathways, increasing lipolysis and fat oxidation while suppressing appetite. They stimulate the glucagon receptor, increasing energy expenditure by promoting glucose production, fat oxidation, and mobilization of energy stores. Triple GLP-1/GIP/glucagon agonists (e.g., retatrutide) have shown preliminary results with similar or improved weight loss and glycemic control compared with dual agonists.[69]

Both GLP-1/GIP agonists and bariatric surgery appear to weaken the biological appetite feedback loops that drive hunger and hinder sustained weight loss. Consequently, the therapeutic advantage of surgical and pharmacological strategies over lifestyle changes lies less in slowing metabolism and more in overriding the hormonally driven increase in appetite that typically triggers weight-loss plateaus and weight regain.[64]

Emerging evidence from animal models suggests that GLP-1 receptor agonist treatment, compared with weight-matched dietary restriction, preserves FFM and may prevent the decline in EE that accompanies calorie-restricted weight loss. In a Göttingen minipig model of obesity, semaglutide treatment resulted in significantly less FFM loss (4.3 kg difference, P < 0.05). It prevented metabolic adaptation compared with calorie-restricted animals, despite similar weight trajectories.[70] These effects were likely mediated by the preservation of mitochondrial proton leak and resting myosin ATP consumption in skeletal muscle, representing novel mechanisms for regulating energy expenditure during pharmacologically induced weight loss.[71][72][73]

Beyond incretin-based therapies, novel molecular targets for obesity treatment are emerging. Recent animal studies have identified hypothalamic Salt-Inducible Kinase 3 (SIK3) as a key regulator of energy balance. SIK3 expression is elevated in the hypothalamus of obese mice, and selective inactivation of SIK3 in orexigenic NPY neurons reduces food intake, increases energy expenditure, and enhances white adipose tissue browning, thereby conferring resistance to high-fat diet-induced obesity. Pharmacological inhibition of SIK3 in diet-induced obese mice led to significant weight reduction and improved metabolic health by enhancing central leptin and insulin signaling. These findings reveal a previously unidentified SIK3-mediated pathway that promotes positive energy balance and suggest that SIK3 inhibition may be a future treatment for obesity and metabolic disorders.[74]

Enhancing Healthcare Team Outcomes

Managing the metabolic consequences of weight loss requires an interprofessional healthcare team dedicated to long-term weight maintenance, and current clinical guidelines recommend structured programs that extend beyond 1 year.[75] Because weight reduction triggers strong compensatory neuroendocrine adaptations, team members must recognize that weight regain is a biologically defended survival mechanism rather than a failure of patient willpower. Without ongoing interprofessional support, weight regain can reach 50% to 80% of the total weight lost within 3 to 5 years.[76] 

To optimize outcomes, a team of primary care and specialist physicians, bariatric surgeons, advanced practice clinicians, nurses, dietitians, exercise physiologists, clinical pharmacists, and mental health specialists should monitor patients every 3 to 6 months. This ongoing evaluation must extend beyond BMI to track changes in body composition, with a focus on preserving FFM and managing obesity-related comorbidities, including type 2 diabetes, cardiovascular disease, and MASLD.[76][77][78]

Clinical pharmacists and prescribers collaborate closely to manage anti-obesity medications, assess adherence, manage side effects, and coordinate dosage titration during the weight-maintenance phase.[79] For patients considering bariatric surgery, the team must coordinate comprehensive preoperative psychological and nutritional clearances, as well as post-surgical follow-up.

Registered dietitians work with the medical team to design meal plans that provide balanced caloric intake, prevent nutritional deficiencies, and ensure adequate protein to prevent diet-induced sarcopenia.[80] Exercise physiologists and physical trainers develop targeted resistance and endurance protocols (≥2 days/week) to preserve FFM, thereby sustaining REE and optimizing insulin sensitivity. Nurses and laboratory technologists form the operational backbone of long-term surveillance. Nurses serve as the primary point of contact, providing patient counseling, monitoring for weight regain, and coordinating referrals when a patient requires a higher level of care. Laboratory professionals ensure accurate, timely results for tracking metabolic markers, lipid panels, and hepatic enzymes, and for documenting resolution of comorbidities.[81] The care team should leverage digital health tools, including mobile tracking applications and telehealth platforms, to improve real-time patient feedback, sustain clinical engagement, and provide timely counseling between face-to-face visits.

Ultimately, treating obesity as a chronic, relapsing disease through integrated interprofessional communication, collaborative decision-making, ongoing patient education, and a shared therapeutic plan aims to significantly reduce the rate of weight regain and improve patients' overall metabolic health.[82] 

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Mulder CJJ, Bayoumy AB, Ansari AR. The 'Obesity First' approach: Redefining the future of healthcare. Indian J Gastroenterol. 2026 Feb;45(1):15-19. [PMC free article: PMC12920710] [PubMed: 41152558]

2.

Bajaj SS, Zhong A, Zhang AL, Stanford FC. Body Mass Index Thresholds for Asians: A Race Correction in Need of Correction? Ann Intern Med. 2024 Aug;177(8):1127-1129. [PMC free article: PMC11707652] [PubMed: 39038288]

3.

Li Z, Daniel S, Fujioka K, Umashanker D. Obesity among Asian American people in the United States: A review. Obesity (Silver Spring). 2023 Feb;31(2):316-328. [PMC free article: PMC10108164] [PubMed: 36695056]

4.

Shen S, Brown KA, Green AK, Iyengar NM. Obesity and Cancer: A Translational Science Review. JAMA. 2026 Apr 21;335(15):1341-1350. [PubMed: 41801209]

5.

Brown JC, Carson TL, Thompson HJ, Agurs-Collins T. The Triple Health Threat of Diabetes, Obesity, and Cancer-Epidemiology, Disparities, Mechanisms, and Interventions. Obesity (Silver Spring). 2021 Jun;29(6):954-959. [PMC free article: PMC8152945] [PubMed: 34029445]

6.

Kaw R, Wong J, Mokhlesi B. Obesity and Obesity Hypoventilation, Sleep Hypoventilation, and Postoperative Respiratory Failure. Anesth Analg. 2021 May 01;132(5):1265-1273. [PubMed: 33857968]

7.

Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP., American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010. [PMC free article: PMC8493650] [PubMed: 33882682]

8.

Yim HE, Yoo KH. Obesity and chronic kidney disease: prevalence, mechanism, and management. Clin Exp Pediatr. 2021 Oct;64(10):511-518. [PMC free article: PMC8498012] [PubMed: 33831296]

9.

Zhang P, Atkinson KM, Bray GA, Chen H, Clark JM, Coday M, Dutton GR, Egan C, Espeland MA, Evans M, Foreyt JP, Greenway FL, Gregg EW, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Huckfeldt PJ, Jackson SD, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Killean T, Knowler WC, Korytkowski M, Lewis CE, Maruthur NM, Michaels S, Montez MG, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Redmon B, Rushing JT, Steinburg H, Wadden TA, Wing RR, Wyatt H, Yanovski SZ., Look AHEAD Research Group. Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study. Diabetes Care. 2021 Jan;44(1):67-74. [PMC free article: PMC7783933] [PubMed: 33168654]

10.

Ketenci YB, Demiröz H, Akca M. TIME-RESTRICTED EATING IN MASLD: THE IMPERATIVE TO PRESERVE MUSCLE MASS AND PREVENT WEIGHT CYCLING FOR SUSTAINABLE CLINICAL BENEFIT. Arq Gastroenterol. 2026;63:e25111. [PMC free article: PMC13200563] [PubMed: 42207075]

11.

Stefan N, Birkenfeld AL, Schulze MB. Global pandemics interconnected - obesity, impaired metabolic health and COVID-19. Nat Rev Endocrinol. 2021 Mar;17(3):135-149. [PubMed: 33479538]

12.

Wang J, Sato T, Sakuraba A. Coronavirus Disease 2019 (COVID-19) Meets Obesity: Strong Association between the Global Overweight Population and COVID-19 Mortality. J Nutr. 2021 Jan 04;151(1):9-10. [PMC free article: PMC7890648] [PubMed: 33188432]

13.

Kuk JL, Christensen RAG, Wharton S. Absolute Weight Loss, and Not Weight Loss Rate, Is Associated with Better Improvements in Metabolic Health. J Obes. 2019;2019:3609642. [PMC free article: PMC6374859] [PubMed: 30838133]

14.

Bawden SJ, Stephenson MC, Ciampi E, Hunter K, Marciani L, Macdonald IA, Aithal GP, Morris PG, Gowland PA. Investigating the effects of an oral fructose challenge on hepatic ATP reserves in healthy volunteers: A (31)P MRS study. Clin Nutr. 2016 Jun;35(3):645-9. [PubMed: 25935852]

15.

Compher C, Frankenfield D, Keim N, Roth-Yousey L., Evidence Analysis Working Group. Best practice methods to apply to measurement of resting metabolic rate in adults: a systematic review. J Am Diet Assoc. 2006 Jun;106(6):881-903. [PubMed: 16720129]

16.

Strath SJ, Kaminsky LA, Ainsworth BE, Ekelund U, Freedson PS, Gary RA, Richardson CR, Smith DT, Swartz AM., American Heart Association Physical Activity Committee of the Council on Lifestyle and Cardiometabolic Health and Cardiovascular, Exercise, Cardiac Rehabilitation and Prevention Committee of the Council on Clinical Cardiology, and Council. Guide to the assessment of physical activity: Clinical and research applications: a scientific statement from the American Heart Association. Circulation. 2013 Nov 12;128(20):2259-79. [PubMed: 24126387]

17.

Most J, Redman LM. Impact of calorie restriction on energy metabolism in humans. Exp Gerontol. 2020 May;133:110875. [PMC free article: PMC9036397] [PubMed: 32057825]

18.

Müller MJ, Enderle J, Pourhassan M, Braun W, Eggeling B, Lagerpusch M, Glüer CC, Kehayias JJ, Kiosz D, Bosy-Westphal A. Metabolic adaptation to caloric restriction and subsequent refeeding: the Minnesota Starvation Experiment revisited. Am J Clin Nutr. 2015 Oct;102(4):807-19. [PubMed: 26399868]

19.

Edinburgh RM, Koumanov F, Gonzalez JT. Impact of pre-exercise feeding status on metabolic adaptations to endurance-type exercise training. J Physiol. 2022 Mar;600(6):1327-1338. [PMC free article: PMC11497303] [PubMed: 33428210]

20.

Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, de las Fuentes L, He S, Okunade AL, Patterson BW, Klein S. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016 Apr 12;23(4):591-601. [PMC free article: PMC4833627] [PubMed: 26916363]

21.

Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017 Apr 13;376(15):1492. [PubMed: 28402780]

22.

Weiss EP, Albert SG, Reeds DN, Kress KS, McDaniel JL, Klein S, Villareal DT. Effects of matched weight loss from calorie restriction, exercise, or both on cardiovascular disease risk factors: a randomized intervention trial. Am J Clin Nutr. 2016 Sep;104(3):576-86. [PMC free article: PMC4997297] [PubMed: 27465384]

23.

Montefusco L, D'Addio F, Loretelli C, Ben Nasr M, Garziano M, Rossi A, Pastore I, Plebani L, Lunati ME, Bolla AM, Porta MD, Piuri G, Rocchio F, Abdelsalam A, Assi E, Barichella M, Maestroni A, Usuelli V, Loreggian L, Muzio F, Zuccotti GV, Cazzola R, Fiorina P. Anti-inflammatory effects of diet and caloric restriction in metabolic syndrome. J Endocrinol Invest. 2021 Nov;44(11):2407-2415. [PMC free article: PMC8502121] [PubMed: 33686615]

24.

Adapa S, Fahey P, Piya M, Birhanu F, Atlantis E. Effect of Clinically Significant Weight Loss on Remission of Metabolic Complications: A Rapid Review and Meta-Analysis of Comparative Controlled Studies. Obes Rev. 2026 Jul;27(7):e70091. [PubMed: 41527354]

25.

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013 Jun 06;153(6):1194-217. [PMC free article: PMC3836174] [PubMed: 23746838]

26.

Bosch-Sierra N, Grau-Del Valle C, Hermenejildo J, Hermo-Argibay A, Salazar JD, Garrido M, Navajas-Porras B, Sáez G, Morillas C, Bañuls C. The Impact of Weight Loss on Inflammation, Oxidative Stress, and Mitochondrial Function in Subjects with Obesity. Antioxidants (Basel). 2024 Jul 19;13(7) [PMC free article: PMC11273387] [PubMed: 39061938]

27.

Nymo S, Coutinho SR, Torgersen LH, Bomo OJ, Haugvaldstad I, Truby H, Kulseng B, Martins C. Timeline of changes in adaptive physiological responses, at the level of energy expenditure, with progressive weight loss. Br J Nutr. 2018 Jul;120(2):141-149. [PMC free article: PMC6088538] [PubMed: 29733003]

28.

Camps SG, Verhoef SP, Westerterp KR. Weight loss, weight maintenance, and adaptive thermogenesis. Am J Clin Nutr. 2013 May;97(5):990-4. [PubMed: 23535105]

29.

Edwards KL, Prendergast LA, Kalfas S, Sumithran P, Proietto J. Impact of starting BMI and degree of weight loss on changes in appetite-regulating hormones during diet-induced weight loss. Obesity (Silver Spring). 2022 Apr;30(4):911-919. [PMC free article: PMC9310603] [PubMed: 35253406]

30.

Thom G, Dombrowski SU, Brosnahan N, Algindan YY, Rosario Lopez-Gonzalez M, Roditi G, Lean MEJ, Malkova D. The role of appetite-related hormones, adaptive thermogenesis, perceived hunger and stress in long-term weight-loss maintenance: a mixed-methods study. Eur J Clin Nutr. 2020 Apr;74(4):622-632. [PubMed: 32020057]

31.

Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. [PubMed: 22029981]

32.

van Baak MA, Mariman ECM. Mechanisms of weight regain after weight loss - the role of adipose tissue. Nat Rev Endocrinol. 2019 May;15(5):274-287. [PubMed: 30655624]

33.

Mai K, Li L, Wiegand S, Brachs M, Leupelt V, Ernert A, Kühnen P, Hübner N, Robinson P, Chen W, Krude H, Spranger J. An Integrated Understanding of the Molecular Mechanisms of How Adipose Tissue Metabolism Affects Long-term Body Weight Maintenance. Diabetes. 2019 Jan;68(1):57-65. [PubMed: 30389745]

34.

Jin Z, Li J, Thackray AE, Shen T, Deighton K, King JA, Stensel DJ. Fasting appetite-related gut hormone responses after weight loss induced by calorie restriction, exercise, or both in people with overweight or obesity: a meta-analysis. Int J Obes (Lond). 2025 May;49(5):776-792. [PMC free article: PMC12095072] [PubMed: 39929932]

35.

Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002 May 23;346(21):1623-30. [PubMed: 12023994]

36.

Agnihothri RV, Courville AB, Linderman JD, Smith S, Brychta R, Remaley A, Chen KY, Simchowitz L, Celi FS. Moderate weight loss is sufficient to affect thyroid hormone homeostasis and inhibit its peripheral conversion. Thyroid. 2014 Jan;24(1):19-26. [PMC free article: PMC3887425] [PubMed: 23902316]

37.

Shekhar S, Tessa Tonleu J, Okigbo CC, Leka H, Kim AE, Purse BP, Hirsch KR, Stolze BR, McGrath JA, Smith-Ryan AE, Soldin SJ, Hall JE. Thyroid axis adaptations to moderate short-term energy restriction in healthy, young women. Eur J Endocrinol. 2025 Apr 30;192(5):568-576. [PMC free article: PMC12062748] [PubMed: 40265345]

38.

Misra M, Klibanski A. Endocrine consequences of anorexia nervosa. Lancet Diabetes Endocrinol. 2014 Jul;2(7):581-92. [PMC free article: PMC4133106] [PubMed: 24731664]

39.

Huang YN, Liao WL, Huang JY, Lin YJ, Yang SF, Huang CC, Wang CH, Su PH. Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study. Diabetes Obes Metab. 2024 Nov;26(11):5222-5232. [PubMed: 39171569]

40.

Heymsfield SB, Brown J, Ramirez S, Prado CM, Tinsley GM, Gonzalez MC. Are Lean Body Mass and Fat-Free Mass the Same or Different Body Components? A Critical Perspective. Adv Nutr. 2024 Dec;15(12):100335. [PMC free article: PMC11625996] [PubMed: 39510253]

41.

von Haehling S, Sato R, Langer H, Khan MS, Coats AJS, Evans W, Heymsfield S, Anker SD. Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. J Cachexia Sarcopenia Muscle. 2025 Dec;16(6):e70147. [PMC free article: PMC12686571] [PubMed: 41362110]

42.

Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026 Jun;28(6):4818-4827. [PubMed: 41877354]

43.

Ross R, Soni S, Houle SA. Negative Energy Balance Induced by Exercise or Diet: Effects on Visceral Adipose Tissue and Liver Fat. Nutrients. 2020 Mar 25;12(4) [PMC free article: PMC7230996] [PubMed: 32218121]

44.

Ristow M, Zarse K. How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). Exp Gerontol. 2010 Jun;45(6):410-8. [PubMed: 20350594]

45.

Deller M, Weiershaus J, Held S, Brinkmann C. Effects of Calorie Restriction With and Without Strength, Endurance or Mixed Training on Fat-Free and Skeletal Muscle Mass in Overweight or Obese Individuals-A Systematic Review With Pairwise Meta-Analysis and Network Meta-Analysis of Randomized Controlled Studies. Diabetes Obes Metab. 2026 Aug;28(8):6810-6823. [PMC free article: PMC13341414] [PubMed: 42144246]

46.

Lahav Y, Yavetz R, Gepner Y. Resistance training as a key strategy for high-quality weight loss in men and women. Front Endocrinol (Lausanne). 2025;16:1725500. [PMC free article: PMC12851882] [PubMed: 41625248]

47.

Evans EM, Straight CR, Reed RA, Berg AC, Rowe DA, Johnson MA. Exercise and Protein Effects on Strength and Function with Weight Loss in Older Women. Med Sci Sports Exerc. 2021 Jan;53(1):183-191. [PubMed: 32520876]

48.

Legrand MA, Paccou J, Lecerf JM, Thomas T, Chapurlat R, Cortet B, Biver E, Papageorgiou M. Bone Health Following Lifestyle-Induced Weight Loss in Individuals With Overweight/Obesity: A Narrative Review. Obesity (Silver Spring). 2026 Jan;34(1):19-35. [PMC free article: PMC12724040] [PubMed: 41070756]

49.

Paccou J, Compston JE. Bone health in adults with obesity before and after interventions to promote weight loss. Lancet Diabetes Endocrinol. 2024 Oct;12(10):748-760. [PubMed: 39053479]

50.

Rizzoli R, Biver E, Brennan-Speranza TC. Nutritional intake and bone health. Lancet Diabetes Endocrinol. 2021 Sep;9(9):606-621. [PubMed: 34242583]

51.

Palermo A, Tsourdi E, Yavropoulou MP, Naciu AM, Tabacco G, Makras P, Paccou J, Anastasilakis AD. The Effects of Obesity and Weight Loss Interventions on Bone Health: A Narrative Review. Curr Diab Rep. 2025 Oct 08;25(1):52. [PubMed: 41060517]

52.

Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker SL, Swinburn BA. Quantification of the effect of energy imbalance on bodyweight. Lancet. 2011 Aug 27;378(9793):826-37. [PMC free article: PMC3880593] [PubMed: 21872751]

53.

De la Peña-Armada R, Longo-Silva G, Rodríguez-Martín M, Yang HW, Garaulet M. Key Determinants of Weight Loss Trajectory Across Different Periods of a Behavioral Weight Loss Intervention. Obesity (Silver Spring). 2026 Feb;34(2):357-371. [PMC free article: PMC12850559] [PubMed: 41559528]

54.

Keating MK, Woodruff RK, Saner EM. Management of Obesity: Office-Based Strategies. Am Fam Physician. 2024 Aug;110(2):145-156. [PubMed: 39172672]

55.

Ashtary-Larky D, Bagheri R, Abbasnezhad A, Tinsley GM, Alipour M, Wong A. Effects of gradual weight loss v. rapid weight loss on body composition and RMR: a systematic review and meta-analysis. Br J Nutr. 2020 Dec 14;124(11):1121-1132. [PubMed: 32576318]

56.

Carlsund Å, Hörnsten Å, Hoosen F, Amoah S, Otten J. Navigating ambivalence: perspectives on healthy eating habits and readiness for change among Swedish men with prediabetes. Front Clin Diabetes Healthc. 2026;7:1793053. [PMC free article: PMC13216768] [PubMed: 42221014]

57.

Unick JL, Neiberg RH, Hogan PE, Cheskin LJ, Dutton GR, Jeffery R, Nelson JA, Pi-Sunyer X, West DS, Wing RR., Look AHEAD Research Group. Weight change in the first 2 months of a lifestyle intervention predicts weight changes 8 years later. Obesity (Silver Spring). 2015 Jul;23(7):1353-6. [PMC free article: PMC4481874] [PubMed: 26110890]

58.

American Diabetes Association Professional Practice Committee for Diabetes*. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 01;49(Supplement_1):S89-S131. [PMC free article: PMC12690188] [PubMed: 41358898]

59.

Mariam A, Miller-Atkins G, Pantalone KM, Iyer N, Misra-Hebert AD, Milinovich A, Bauman J, Mocarski M, Ramasamy A, Smolarz BG, Hobbs TM, Zimmerman RS, Burguera B, Kattan MW, Rotroff DM. Associations of weight loss with obesity-related comorbidities in a large integrated health system. Diabetes Obes Metab. 2021 Dec;23(12):2804-2813. [PMC free article: PMC9292723] [PubMed: 34472680]

60.

Lingvay I, Cohen RV, Roux CWL, Sumithran P. Obesity in adults. Lancet. 2024 Sep 07;404(10456):972-987. [PubMed: 39159652]

61.

Martins C, Roekenes JA, Rehfeld JF, Hunter GR, Gower BA. Metabolic adaptation is associated with a greater increase in appetite following weight loss: a longitudinal study. Am J Clin Nutr. 2023 Dec;118(6):1192-1201. [PubMed: 37863431]

62.

van Baak MA, Mariman ECM. Obesity-induced and weight-loss-induced physiological factors affecting weight regain. Nat Rev Endocrinol. 2023 Nov;19(11):655-670. [PubMed: 37696920]

63.

Lopez Torres SY, Aukan MI, Gower BA, Martins C. Adaptive thermogenesis, at the level of resting energy expenditure, after diet alone or diet plus bariatric surgery. Obesity (Silver Spring). 2024 Jun;32(6):1169-1178. [PMC free article: PMC11132925] [PubMed: 38664956]

64.

Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity (Silver Spring). 2024 Jun;32(6):1163-1168. [PMC free article: PMC11132924] [PubMed: 38644683]

65.

Falkenhain K, Martin CK, Ravussin E, Redman LM. Energy expenditure, metabolic adaptation, physical activity and energy intake following weight loss: comparison between bariatric surgery and low-calorie diet. Eur J Clin Nutr. 2025 Dec;79(12):1174-1179. [PMC free article: PMC12041307] [PubMed: 39478234]

66.

Karppinen JE, Heinonen S, Saarinen T, van der Kolk BW, Säiläkivi U, Sammalkorpi H, Penttilä AK, Groop PH, Juuti A, Pietiläinen KH. Changes in body composition and resting energy expenditure during the first year after Roux-en-Y or one-anastomosis gastric bypass. Am J Physiol Endocrinol Metab. 2026 Mar 01;330(3):E287-E297. [PubMed: 41556842]

67.

Rabl C, Rao MN, Schwarz JM, Mulligan K, Campos GM. Thermogenic changes after gastric bypass, adjustable gastric banding or diet alone. Surgery. 2014 Oct;156(4):806-12. [PMC free article: PMC4171693] [PubMed: 25239323]

68.

Alissou M, Demangeat T, Folope V, Van Elslande H, Lelandais H, Blanchemaison J, Cailleaux PE, Guney S, Aupetit A, Aubourg A, Rapp C, Petit A, Godin M, Vignal L, Grigioni S, Déchelotte P, Colange G, Coëffier M, Achamrah N. Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study. Diabetes Obes Metab. 2026 Jan;28(1):112-121. [PMC free article: PMC12673431] [PubMed: 41068996]

69.

Wen J, Nadora D, Truong A, Bernstein E, How-Volkman C, Razick A, Razick D, Karabala M, Frezza E. Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review. Nutr Metab Cardiovasc Dis. 2025 Dec;35(12):104213. [PubMed: 40685266]

70.

Chen KE, Wang PC, Lin HA, Lin SF. Risk of Age-Related Ocular Diseases in Non-Diabetic Adults With Obesity Using Glucagon-Like Peptide 1 Receptor Agonists. Diabetes Obes Metab. 2026 Aug;28(8):7580-7591. [PMC free article: PMC13341374] [PubMed: 42259622]

71.

Bredum SK, Jacobsen JM, Halling JF, Blom I, Lewis CTA, Ochala J, Fredholm M, Lundh S, Schmücker M, Ozenne B, Domingos AI, Hald B, Larsen S, Cirera S, Christoffersen BØ. Semaglutide mitigates the loss of fat-free mass and decreased energy expenditure observed after diet restriction. Insights from an obese minipig model. Am J Physiol Endocrinol Metab. 2026 Apr 01;330(4):E401-E410. [PubMed: 41671030]

72.

Dahl K, Toubro S, Dey S, Duque do Vale R, Flint A, Gasiorek A, Heydorn A, Jastreboff AM, Key C, Petersen SB, Vegge A, Adelborg K. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet. 2025 Jul 12;406(10499):149-162. [PubMed: 40550231]

73.

Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, Ryan DH, Still CD., Endocrine Society. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015 Feb;100(2):342-62. [PubMed: 25590212]

74.

Onda DA, Yang CH, Goldsmith C, Beddows CA, Teo RQ, Zhang L, Yuan X, Zhu Y, Lee MK, Ovens AJ, Yu D, Sakamoto K, Scott JW, Murphy AJ, Tsumaki N, Herzog H, Dodd GT, Loh K. Targeting hypothalamic SIK3 to promote weight loss and improve glycemic control in mice. Nat Commun. 2026 Jun 02; [PubMed: 42230648]

75.

American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring). 2014 Jul;22 Suppl 2:S5-39. [PubMed: 24961825]

76.

Kirkpatrick CF, Bolick JP, Kris-Etherton PM, Sikand G, Aspry KE, Soffer DE, Willard KE, Maki KC. Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force. J Clin Lipidol. 2019 Sep-Oct;13(5):689-711.e1. [PubMed: 31611148]

77.

Stubbs RJ, Duarte C, Palmeira AL, Sniehotta FF, Horgan G, Larsen SC, Marques MM, Evans EH, Ermes M, Harjumaa M, Turicchi J, O'Driscoll R, Scott SE, Pearson B, Ramsey L, Mattila E, Matos M, Sacher P, Woodward E, Mikkelsen ML, Sainsbury K, Santos I, Encantado J, Stalker C, Teixeira PJ, Heitmann BL. Evidence-Based Digital Tools for Weight Loss Maintenance: The NoHoW Project. Obes Facts. 2021;14(3):320-333. [PMC free article: PMC8255638] [PubMed: 33915534]

78.

Roberts CA, Christiansen P, Halford JCG. Tailoring pharmacotherapy to specific eating behaviours in obesity: Can recommendations for personalised therapy be made from the current data? Acta Diabetol. 2017 Aug;54(8):715-725. [PMC free article: PMC5504125] [PubMed: 28421338]

79.

Petersen J, Finan B, Johansen VBI, Müller TD, Clemmensen C. The evolving landscape of obesity pharmacotherapy. Nat Rev Drug Discov. 2026 May 13; [PubMed: 42129460]

80.

Stewart TM, Bhapkar M, Das S, Galan K, Martin CK, McAdams L, Pieper C, Redman L, Roberts S, Stein RI, Rochon J, Williamson DA., CALERIE Study Group. Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy Phase 2 (CALERIE Phase 2) screening and recruitment: methods and results. Contemp Clin Trials. 2013 Jan;34(1):10-20. [PMC free article: PMC3525758] [PubMed: 22981898]

81.

Wedell-Neergaard AS, Krogh-Madsen R, Petersen GL, Hansen ÅM, Pedersen BK, Lund R, Bruunsgaard H. Cardiorespiratory fitness and the metabolic syndrome: Roles of inflammation and abdominal obesity. PLoS One. 2018;13(3):e0194991. [PMC free article: PMC5874061] [PubMed: 29590212]

82.

Torti J, Luig T, Borowitz M, Johnson JA, Sharma AM, Campbell-Scherer DL. The 5As team patient study: patient perspectives on the role of primary care in obesity management. BMC Fam Pract. 2017 Feb 08;18(1):19. [PMC free article: PMC5299769] [PubMed: 28178930]

Disclosure: Aisha Farhana declares no relevant financial relationships with ineligible companies.

Disclosure: Sharon Daley declares no relevant financial relationships with ineligible companies.

Disclosure: Anis Rehman declares no relevant financial relationships with ineligible companies.